Even as the raw material cost climbed down from 25% of revenues a year ago to 23% in the September quarter, the other expenses increased from 28% of revenues to nearly 32% in the quarter.
Synopsis
The company’s revenues grew 11% driven by strong growth posted by the India business and the global specialty sales in the US. A third of the company’s revenues is earned each from India and the US. Sun’s market share in India increased from 8.3% to 8.4% for the year ended September 2023.
ET Intelligence Group: India’s largest pharma company’s pivot to global specialty drugs is paying off now. Its September quarter performance was enhanced by the growing traction of its specialty product portfolio. With an 11% surge in revenues and 5% rise in profits, the Street cheered the performance leading to the stock closing 2.5% higher on Wednesday.The company’s revenues grew 11% driven by strong growth posted by the India business and the
AbcSmall
AbcMedium
AbcLarge
SAVEPRINTCOMMENT
Continue reading with one of these options:
Limited Access
Free
Login to get access to some exclusive stories& personalised newsletters
Login Now
Unlimited Access
Starting @ Rs120/month
Get access to exclusive stories, expert opinions &in-depth stock reports
Subscribe Now
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Sign In to Read for Free
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience withMinimal Ads
Comment & Engage with ET Prime community
Exclusive invites to Virtual Events with Industry Leaders
A trusted team of Journalists & Analysts who can best filter signal from noise
Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-